TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

Search

CSL Ltd

Chiusa

SettoreTop Industriali

257.01 0.65

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

250.43

Massimo

257.24

Metriche Chiave

By Trading Economics

Entrata

1.3B

2B

Vendite

1.5B

8.2B

P/E

Media del settore

28.972

33.198

EPS

1.831

Rendimento da dividendi

1.7

Margine di Profitto

24.437

Dipendenti

32,698

EBITDA

1.5B

3.2B

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+26.05% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

1.70%

2.54%

Prossima data del Dividendo

9 apr 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-14B

121B

Apertura precedente

256.36

Chiusura precedente

257.01

Notizie sul Sentiment di mercato

By Acuity

34%

66%

121 / 468 Classifica in Industrials

CSL Ltd Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

10 feb 2025, 21:55 UTC

Utili

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business -- Update

10 feb 2025, 21:34 UTC

Utili

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business

12 ago 2024, 23:23 UTC

Utili

CSL Annual Profit Rises by 20% on Immunoglobulins Growth -- Update

12 ago 2024, 22:49 UTC

Utili

CSL Annual Profit Rises by 20%, Forecasts Fiscal Year 2025 Underlying Earnings Growth

21 mar 2025, 02:03 UTC

Discorsi di Mercato

Severe U.S. Influenza Season Could Benefit CSL -- Market Talk

11 feb 2025, 22:30 UTC

Discorsi di Mercato

Flu Vaccines Proving Problematic for CSL -- Market Talk

10 feb 2025, 21:40 UTC

Utili

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business -- Update

10 feb 2025, 21:19 UTC

Utili

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business

10 feb 2025, 21:13 UTC

Utili

CSL Reaffirms Guidance for FY 2025 Net Profit of US$3.2 Billion-US$3.3 Billion at Constant FX

10 feb 2025, 21:12 UTC

Utili

CSL Interim Dividend US$1.30/Security

10 feb 2025, 21:12 UTC

Utili

CSL 1H Revenue US$8.48 Billion, Up 5% on Year

10 feb 2025, 21:11 UTC

Utili

CSL 1H Net Profit US$2.07 Billion, Up 3% on Year

7 nov 2024, 03:53 UTC

Discorsi di Mercato

U.S. Tariffs Could Force Moves by Australian Med-Techs -- Market Talk

22 ott 2024, 22:53 UTC

Discorsi di Mercato

CSL's R&D Update Seen as Neutral Overall -- Market Talk

10 ott 2024, 22:20 UTC

Discorsi di Mercato

CSL Bull Looking for Update on Gross Margin -- Market Talk

13 ago 2024, 00:33 UTC

Discorsi di Mercato

CSL Profit Outlook Looks Weaker Than Expected -- Market Talk

12 ago 2024, 22:34 UTC

Utili

CSL Annual Profit Rises by 20%, Forecasts FY 2025 Underlying Earnings Growth

12 ago 2024, 22:18 UTC

Utili

CSL Expects FY2025 Revenue Growth of Roughly 5%-7% at Constant Currency

12 ago 2024, 22:18 UTC

Utili

CSL: Conditions for Seqirus Remain Challenging, But Unit Expected to Outperform Market

12 ago 2024, 22:17 UTC

Utili

CSL: Has a Number of Efficiency Initiatives Underway in Plasma Collections, Manufacturing Operations

12 ago 2024, 22:16 UTC

Utili

CSL: Momentum in Behring Seen Underpinned by Strong Patient Demand in Immunoglobulins

12 ago 2024, 22:15 UTC

Utili

CSL: Remains Confident in Medium-Term Double-Digit Earnings Growth Target

12 ago 2024, 22:14 UTC

Utili

CSL: Vifor Continues to Grow Iron Volume in Europe Despite Generic Entrants

12 ago 2024, 22:13 UTC

Utili

CSL Expects FY2025 Underlying Profit Up Between 10%-13% on Constant Currency Basis

12 ago 2024, 22:13 UTC

Utili

CSL Expects FY2025 Underlying Profit Between US$3.2 Billion-US$3.3 Billion

12 ago 2024, 22:11 UTC

Utili

CSL: Outlook for Behring Positive But Competitive Pressures Increased Recently

12 ago 2024, 22:10 UTC

Utili

CSL FY Underlying Profit Up 15% on Constant Currency Basis to US$3.01 Billion

12 ago 2024, 22:09 UTC

Utili

CSL FY Revenue US$14.80 Billion, Up 11% On-Year

12 ago 2024, 22:08 UTC

Utili

CSL FY Underlying Profit US$2.91 Billion, Up 11% On-Year

12 ago 2024, 22:07 UTC

Utili

CSL FY Net Profit US$2.64 Billion, Up 20% On-Year

Confronto tra pari

Modifica del prezzo

CSL Ltd Previsione

Obiettivo di Prezzo

By TipRanks

26.05% in crescita

Previsioni per 12 mesi

Media 317.092 AUD  26.05%

Alto 360.3 AUD

Basso 250 AUD

Basato su 14 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per CSL Ltd - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

14 ratings

12

Acquista

2

Mantieni

0

Vendi

Sentiment

By Acuity

121 / 468 Classifica in Top Industriali

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo CSL Ltd

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.